Pure Global AI
NCT05725109Enrolling by invitation

Hepatitis C Diagnosis to Treatment Management

Hepatitis C Disease Management: Diagnosis to Treatment Alerts in CHORUS™
EpividianClinicalTrials.govother
Verified
Study focus
Disease/Condition
Hepatitis C
Drug/Device/Intervention
Hepatitis C Treatment Alerts in CHORUS™
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Epividian
Location
Los Angeles, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jan 09, 2023
End date
Oct 09, 2023
Enrollment
3500 participants
Primary outcome

Prescriptions for HCV treatment

Summary

The objective of this study is to evaluate whether sending alerts to healthcare providers and
 clinic staff to identify patients with untreated hepatitis C infection can increase the
 uptake of hepatitis C treatment. A period of time without alerts will be compared to a period
 of time with alerts.

ICD-10 classifications
Acute hepatitis CChronic viral hepatitis CViral hepatitisChronic viral hepatitisUnspecified viral hepatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05725109
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05725109 through Pure Global AI's free database. This phase not specified trial is sponsored by Epividian and is currently Enrolling by invitation. The study focuses on Hepatitis C. Target enrollment is 3500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.